BridgeMD
New treatment option for Acute Kidney Injury
Official title Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient
ClinicalTrials.gov ID: NCT06369064
What this study is testing
- What it's testing
- In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients hospitalized in ICU
- Undergo RRT session because of AKI stage 3
- At least one among criteria: pH \ 30mM / Fluid overload uncontrolled by with PaCO₂ \< 35 mmHg or mixed acidosis with PaCO₂ \< 50 mmHg.
- Oliguria lasting 72 hours or longer
- Patients undergoing their first session of extracorporeal blood purification, initiated less than 12 hours prior to randomization
You likely can't join if
- End-stage chronic kidney disease on dialysis
- Intoxication with a dialyzable toxin (lithium
- Criteria for emergency dialysis initiation: hyperkaliemia \>6,5mM with electrocardiographic signs
- Medical contraindication to regional citrate: severe liver failure
- Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding
- Pregnant women, parturient or breast-feeding patient
See the full eligibility criteria
- Adult patients hospitalized in ICU
- Undergo RRT session because of AKI stage 3
- At least one among criteria: pH \ 30mM / Fluid overload uncontrolled by with PaCO₂ \< 35 mmHg or mixed acidosis with PaCO₂ \< 50 mmHg.
- Oliguria lasting 72 hours or longer
- Patients undergoing their first session of extracorporeal blood purification, initiated less than 12 hours prior to randomization
- Patient having given free and informed consent, and having signed the consent form or patient included in an emergency situation
- Patient affiliated with Social Security.
- End-stage chronic kidney disease on dialysis
- Intoxication with a dialyzable toxin (lithium
- Criteria for emergency dialysis initiation: hyperkaliemia \>6,5mM with electrocardiographic signs
- Medical contraindication to regional citrate: severe liver failure
- Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding
- Pregnant women, parturient or breast-feeding patient
The study team makes the final eligibility decision.
Where it's taking place
- Nîmes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nîmes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.